CHOP-keemiaraviprotokolli kõrvalmõjude esinemus ravi teostamise ajal lümfoomiga koertele Eesti Maaülikooli Väikeloomakliiniku ja Maxi Lemmikloomakliiniku patsientide alusel
Laen...
Kuupäev
2025
Kättesaadav alates
04.09.2025
Autorid
Ajakirja pealkiri
Ajakirja ISSN
Köite pealkiri
Kirjastaja
Eesti Maaülikool
Abstrakt
Koerte lümfoom on üks sagedaseimad koertel esinevaid neoplaasia tüüpe. Lümfoomi ravivalikud
on väga varieeruvad, sõltudes ravimite kättesaadavusest, omanike soovidest ja majanduslikust
võimekusest ning koera iseloomust. Kuldstandard koerte lümfoomi raviks on süsteemne
keemiaravi kasutades CHOP-keemiaraviprotokolli (ingl – cyclophosphamide,
hydroxydaunorubicin/doxyrubicin, Oncovin/vincristine, prednisolone; CHOP). Keemiaravi
teostamise ajal peab koer end tundma kliiniliselt hästi, mistõttu on oluline fikseerida kõik
esinevad kõrvalmõjud.
Käesoleva kirjeldava juhtude uuringu eesmärgiks oli hinnata CHOP-keemiaraviprotokolli vältel
esinevaid kõrvalmõjusid, mis tekkisid Eesti Maaülikooli Väikeloomakliinikus või Maxi
Lemmikloomakliinikus lümfoomiga koertel, keda raviti CHOP-keemiaraviprotokolli järgi
vahemikus 12.2022-01.2025. Andmeid koguti mõlema loomakliiniku Provet Cloud©
haldussüsteemist ning valimisse kuulusid seitse koera, kes läbisid antud perioodil CHOPkeemiaraviprotokolli
täies ulatuses. Andmeid korrastati ja analüüsiti kasutades Microsoft Office
Excel 2025 programmi.
Kokku esines kõrvalmõjusid selle perioodi vältel 73, millest 38 (52,1%) olid hematoloogilised
kõrvalekalded ja 35 (47,9%) kliinilised kõrvalmõjud. Gastrointestinaalsed kõrvalmõjud
moodustasid kõigist kõrvalmõjudest 17,8%, müelosupressiivsed 46,8%. Kõrvalmõjud esinesid
vähemalt ühe korra kõigil uuringus osalenud koertel. Kõigist esinenud kõrvalmõjudest 65 ehk
89% kuulusid VCOG-CTCAE hindamissüsteemi järgi 1. klassi, kuus kõrvalmõju ehk 9,6%
kuulusid 2. klassi ning üks kõrvalmõju (1,4% kõigist kõrvalmõjudest) kuulus 3. klassi. Ükski
koer ei vajanud hospitaliseerimist. Varasema kirjandusega võrreldes oli antud uuringus suurem
hematoloogiliste ja müelosupressiivsete kõrvalmõjude osakaal, mis võis tuleneda väikesest
uurimispopulatsioonist, lisaks jäid antud uuringus valimist välja koerad, kes ei läbinud CHOPkeemiaraviprotokolli
täielikult, mistõttu võis olla tõsiste kõrvalmõjude osakaal alaesindatud.
Autor näeb antud uuringu väärtust loomaarstide töös, et teadvustada loomaomanikke
kõrvalmõjude suurest esinemissagedusest CHOP-keemiaraviprotokolli ajal ning olla valmis
nende tekkeks ja raviks.
Canine lymphoma is one of the most common types of neoplasias occuring in dogs. The treatment options for canine lymphoma vary widely, depending on the availability of chemotherapy drugs, the wishes and financial means of dog owners and the nature of the dog. The gold standard for treatment of canine lymphoma is systematic chemotherapy following the CHOP-chemotherapy regimen (cyclophosphamide, hydroxydaunorubicin/doxyrubicin, Oncovin/vincristine, prednisolone). Chemotherapy is performed to maintain a good quality of life for the dog, which is why it is important to record any side effects happening during treatment. The aim of this descriptive case series study was to evaluate the incidence of CHOPchemotherapy protocol related side effects in dogs with lymphoma treated in the Small Animal Clinic of the Estonian University of Life Sciences or the Maxi Pet Clinic between 12.2022- 01.2025. The data was collected from the Provet Cloud© management system of both animal clinics and the final sample included seven dogs that completed the CHOP-chemotherapy protocol in full during this period. The data was organised and analysed using Microsoft Office Excel 2025 software. A total of 73 side effects occurred during this period, of which 38 (52.1%) were haematological and 35 (47.9%) clinical side effects. Gastrointestinal side effects accounted for 17.8% and myelosuppressive 46.8% of all adverse events. CHOP-chemotherapy protocol related side effects occurred at least once in all dogs in the study. Of the total amount of side effects that occurred, 65 or 89% were classified as Class 1 according to the VCOG-CTCAE scoring system, six side effects or 9.6% were classified as Class 2 and one side effect (1.4% of all adverse events) was classified as Class 3. None of the dogs required hospitalisation. Compared to previous literature, this study had a higher proportion of haematological and myelosuppressive side effects, which may be due to the small study population. This study also excluded dogs that did not complete the CHOP- chemotherapy protocol in full, which may have underrepresented the proportion of serious adverse events that may have occured. The author sees the value of this study in the work of veterinarians to make pet owners aware of the high incidence of side effects during the CHOP chemotherapy protocol and to be prepared for their occurrence and treatment.
Canine lymphoma is one of the most common types of neoplasias occuring in dogs. The treatment options for canine lymphoma vary widely, depending on the availability of chemotherapy drugs, the wishes and financial means of dog owners and the nature of the dog. The gold standard for treatment of canine lymphoma is systematic chemotherapy following the CHOP-chemotherapy regimen (cyclophosphamide, hydroxydaunorubicin/doxyrubicin, Oncovin/vincristine, prednisolone). Chemotherapy is performed to maintain a good quality of life for the dog, which is why it is important to record any side effects happening during treatment. The aim of this descriptive case series study was to evaluate the incidence of CHOPchemotherapy protocol related side effects in dogs with lymphoma treated in the Small Animal Clinic of the Estonian University of Life Sciences or the Maxi Pet Clinic between 12.2022- 01.2025. The data was collected from the Provet Cloud© management system of both animal clinics and the final sample included seven dogs that completed the CHOP-chemotherapy protocol in full during this period. The data was organised and analysed using Microsoft Office Excel 2025 software. A total of 73 side effects occurred during this period, of which 38 (52.1%) were haematological and 35 (47.9%) clinical side effects. Gastrointestinal side effects accounted for 17.8% and myelosuppressive 46.8% of all adverse events. CHOP-chemotherapy protocol related side effects occurred at least once in all dogs in the study. Of the total amount of side effects that occurred, 65 or 89% were classified as Class 1 according to the VCOG-CTCAE scoring system, six side effects or 9.6% were classified as Class 2 and one side effect (1.4% of all adverse events) was classified as Class 3. None of the dogs required hospitalisation. Compared to previous literature, this study had a higher proportion of haematological and myelosuppressive side effects, which may be due to the small study population. This study also excluded dogs that did not complete the CHOP- chemotherapy protocol in full, which may have underrepresented the proportion of serious adverse events that may have occured. The author sees the value of this study in the work of veterinarians to make pet owners aware of the high incidence of side effects during the CHOP chemotherapy protocol and to be prepared for their occurrence and treatment.
Kirjeldus
Loomaarstiõppe lõputöö
Veterinaarmeditsiini õppekaval
Märksõnad
magistritööd, CHOP-keemiaraviprotokoll, kõrvalmõjud, koerte lümfoom, VCOG-CTCAE